Aptose Biosciences Inc.
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on precision medicines for oncology, with its initial emphasis on hematologic cancers. Its lead asset, tuspetinib, is being developed for acute myeloid leukemia (AML), including combination regimens intended to improve outcomes in newly diagnosed and relapsed/refractory patients. The company also has a broader small-molecule pipeline aimed at enhancing anti-cancer therapy without overlapping toxicities. Aptose is headquartered in Toronto, Canada, with executive offices in San Diego, California, and currently has no marketed products.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueTuspetinib and related AML development activities, including monotherapy and combination regimens.
Research collaboration and trial participation with NCI/CTEP and other clinical networks.
Earlier-stage small-molecule oncology assets such as luxeptinib and related platform work.
Customers
Aptose does not sell commercial products to traditional end customers; its primary counterparties are research institutions, clinical trial networks, regulators, and future oncology treatment centers. In the near term, the company’s 'customers' are effectively trial sponsors and collaborators such as the NCI, which help advance clinical development and generate data needed for approval. If approved, the eventual end users would be hematologists, oncologists, and hospitals treating AML and MDS patients. The commercial value proposition is tied to improving response rates and survival in genetically defined blood-cancer populations where current therapies leave substantial unmet need.
NCI, CTEP, NCTN, NCORP and other research partners that help run trials and generate clinical evidence for tuspetinib.
Hospitals and cancer centers that enroll patients in studies and would adopt approved AML therapies.
Specialists who would use Aptose therapies if approved, especially in AML and MDS settings.
Patients with molecularly defined or relapsed/refractory disease who need more effective treatment options.
Strategy
Aptose’s strategy is centered on advancing tuspetinib through precision-medicine AML development paths that can support accelerated approval or broader frontline use. The company is emphasizing combination therapy, especially TUS+VEN, to address resistance and improve outcomes in genetically diverse AML populations. It is also using the APTIVATE expansion trial to identify patient subsets most likely to respond, which can sharpen the regulatory and commercial case for the asset. Given its limited cash resources, the company is simultaneously pursuing financing, collaborations, and strategic alternatives to sustain development.
Tuspetinib is the company’s lead value driver and the main path to future approval or partnering.
Combination regimens may improve response rates and create a stronger commercial and regulatory profile than monotherapy alone.
The company has going-concern risk and needs capital to continue trials and manufacturing.
Geography
Aptose is operationally split between the United States and Canada, with executive offices in San Diego and a head office in Toronto. Its clinical development footprint is also North American, as the NCI-led myeloMATCH program includes sites in the U.S. and Canada through NCTN and NCORP. The company’s supply chain for clinical drug product is international, including manufacturing support from Hanmi and other third-party producers. Because Aptose is still pre-commercial, geography matters mainly through trial execution, regulatory interactions, and access to financing rather than product sales.
Risks
Aptose faces substantial going-concern and financing risk because it has no material product revenue and limited cash relative to ongoing clinical and manufacturing needs. Its development model depends on third-party suppliers and contract research organizations, so any disruption, contract change, or capacity issue can delay trials and raise costs. Clinical-stage biotech also carries high binary risk: tuspetinib may fail to show sufficient efficacy, safety, or differentiation in AML, which would impair the company’s ability to raise capital or secure approval. In addition, the company is exposed to listing-compliance risk, supply-chain inflation, and geopolitical/tariff pressures that can affect imported drug substance and clinical materials.
- Imminent bankruptcy / going-concern uncertaintyImpact: CriticalLikelihood: High
Management disclosed that cash is insufficient to fund operations for the next 12 months without substantial financing or restructuring.
Exposure: Corporate liquidity and continuity of clinical programs
- Need for immediate capital raisingImpact: CriticalLikelihood: High
The company relies on equity, debt, collaborations, or other financing to fund trials and overhead.
Exposure - Supplier and CRO dependenceImpact: HighLikelihood: High
The company depends on third parties for manufacturing and trial execution, and one CRO represented a large share of accounts payable.
Exposure - Clinical development and regulatory failureImpact: High
Tuspetinib is still in clinical development and may not meet efficacy/safety thresholds for approval.
Exposure: Lead asset value and future commercialization
- Geopolitical and tariff-related supply disruptionImpact: MediumLikelihood: Medium
Imported goods and global supply chains may be affected by tariffs, regulation, and geopolitical tensions.
Exposure: API/drug product availability and cost inflation
Accounting
Judgemental itemsManagement concluded that cash may not be sufficient for the next 12 months, making liquidity disclosure and balance-sheet classification highly judgmental.
Impact: Can affect asset/liability classification and investor perception of solvency
Clinical trials, manufacturing, and preclinical work are expensed as incurred, so timing of vendor activity drives reported losses.
Impact: Creates volatility in quarterly operating results
Option grants, forfeitures, and vesting schedules change non-cash compensation expense period to period.
Impact: Affects reported net loss and operating expense trends
The company relies on CROs and manufacturers, requiring estimates for unpaid services and commitments.
Impact: Can materially affect current liabilities and cash runway analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Apimeds Pharmaceuticals US, Inc.
APUS · Pharmaceutical Preparations
Atossa Therapeutics, Inc
ATOS · Pharmaceutical Preparations
Can-Fite BioPharma Ltd.
CANF · Pharmaceutical Preparations
Adaptive Biotechnologies Corp
ADPT · Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp is a Seattle-based life sciences company built around immune-system sequencing and computational biology.
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026